Where Will Reddit Stock Be In 5 Years?
On a wet March morning last year, the famously orange…
Buy
54
AZN Quote, Financials, Valuation and Earnings
Last price:
$70.98
Seasonality move
:
2.5%
Day range:
$73.41 - $74.76
52-week range:
$61.24 - $87.68
Dividend yield:
2.11%
P/E ratio:
29.54x
P/S ratio:
4.18x
P/B ratio:
5.56x
Volume:
3.4M
Avg. volume:
4.5M
1-year change:
-7.59%
Market cap:
$228B
Revenue:
$54.1B
EPS (TTM):
$2.49
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$13.7B | $1.12 | 8.83% | 84.16% | $84.18 |
|
AMGN
Amgen
|
$8B | $4.26 | 5.67% | 279.07% | $314.70 |
|
BNTX
BioNTech SE
|
$183.4M | -$2.66 | 22.72% | -34.95% | $135.12 |
|
GSK
GSK PLC
|
$10B | $1.04 | 5.94% | 60.08% | $41.54 |
|
MRNA
Moderna
|
$115.3M | -$3.11 | -49.84% | -11.55% | $47.59 |
|
NVAX
Novavax
|
$343.9M | $1.41 | -67.66% | -82.16% | $14.67 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$73.55 | $84.18 | $228B | 29.54x | $1.05 | 2.11% | 4.18x |
|
AMGN
Amgen
|
$295.56 | $314.70 | $158.9B | 26.97x | $2.38 | 3.13% | 4.69x |
|
BNTX
BioNTech SE
|
$106.33 | $135.12 | $25.6B | 191.55x | $0.00 | 0% | 8.62x |
|
GSK
GSK PLC
|
$40.49 | $41.54 | $82.3B | 21.00x | $0.43 | 3.95% | 2.08x |
|
MRNA
Moderna
|
$26.00 | $47.59 | $10.1B | -- | $0.00 | 0% | 3.22x |
|
NVAX
Novavax
|
$7.03 | $14.67 | $1.1B | 2.65x | $0.00 | 0% | 0.96x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
42.02% | 0.266 | 13.05% | 0.69x |
|
AMGN
Amgen
|
90.24% | -0.159 | 34.26% | 0.74x |
|
BNTX
BioNTech SE
|
1.53% | 1.010 | 1.45% | 9.86x |
|
GSK
GSK PLC
|
56.56% | -0.335 | 30.39% | 0.58x |
|
MRNA
Moderna
|
-- | -0.658 | -- | 3.92x |
|
NVAX
Novavax
|
180.06% | 1.623 | 16.39% | 1.84x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$11.3B | $3.7B | 10.93% | 19.55% | 27.61% | $2.7B |
|
AMGN
Amgen
|
$5.2B | $1.2B | 8.85% | 97.08% | 33.08% | $980M |
|
BNTX
BioNTech SE
|
$104.2M | -$562M | -3.86% | -3.91% | -225.11% | -$1.5B |
|
GSK
GSK PLC
|
$7B | $2.8B | 10.19% | 23.08% | 30.2% | $877.6M |
|
MRNA
Moderna
|
$17M | -$1.1B | -29.23% | -29.23% | -900% | -$1.2B |
|
NVAX
Novavax
|
$612.2M | $515.5M | -- | -- | 83.91% | -$187.1M |
AstraZeneca PLC vs. Competitors
-
Which has Higher Returns AZN or AMGN?
Amgen has a net margin of 21.46% compared to AstraZeneca PLC's net margin of 21.23%. AstraZeneca PLC's return on equity of 19.55% beat Amgen's return on equity of 97.08%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC83.51% $0.94 $70.9B AMGNAmgen63.58% $3.20 $63.6B -
What do Analysts Say About AZN or AMGN?
AstraZeneca PLC has a consensus price target of $84.18, signalling upside risk potential of 14.46%. On the other hand Amgen has an analysts' consensus of $314.70 which suggests that it could grow by 6.48%. Given that AstraZeneca PLC has higher upside potential than Amgen, analysts believe AstraZeneca PLC is more attractive than Amgen.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 2 0 AMGNAmgen10 15 2 -
Is AZN or AMGN More Risky?
AstraZeneca PLC has a beta of 0.385, which suggesting that the stock is 61.545% less volatile than S&P 500. In comparison Amgen has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.15%.
-
Which is a Better Dividend Stock AZN or AMGN?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.11%. Amgen offers a yield of 3.13% to investors and pays a quarterly dividend of $2.38 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.
-
Which has Better Financial Ratios AZN or AMGN?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Amgen quarterly revenues of $8.1B. AstraZeneca PLC's net income of $2.9B is higher than Amgen's net income of $1.7B. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.54x while Amgen's PE ratio is 26.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.18x versus 4.69x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.18x 29.54x $13.6B $2.9B AMGNAmgen4.69x 26.97x $8.1B $1.7B
-
Which has Higher Returns AZN or BNTX?
BioNTech SE has a net margin of 21.46% compared to AstraZeneca PLC's net margin of -227.46%. AstraZeneca PLC's return on equity of 19.55% beat BioNTech SE's return on equity of -3.91%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC83.51% $0.94 $70.9B BNTXBioNTech SE54.16% -$1.82 $20.8B -
What do Analysts Say About AZN or BNTX?
AstraZeneca PLC has a consensus price target of $84.18, signalling upside risk potential of 14.46%. On the other hand BioNTech SE has an analysts' consensus of $135.12 which suggests that it could grow by 27.08%. Given that BioNTech SE has higher upside potential than AstraZeneca PLC, analysts believe BioNTech SE is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 2 0 BNTXBioNTech SE13 5 0 -
Is AZN or BNTX More Risky?
AstraZeneca PLC has a beta of 0.385, which suggesting that the stock is 61.545% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.288, suggesting its more volatile than the S&P 500 by 28.759%.
-
Which is a Better Dividend Stock AZN or BNTX?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.11%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or BNTX?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than BioNTech SE quarterly revenues of $192.3M. AstraZeneca PLC's net income of $2.9B is higher than BioNTech SE's net income of -$437.5M. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.54x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.18x versus 8.62x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.18x 29.54x $13.6B $2.9B BNTXBioNTech SE8.62x 191.55x $192.3M -$437.5M
-
Which has Higher Returns AZN or GSK?
GSK PLC has a net margin of 21.46% compared to AstraZeneca PLC's net margin of 21.61%. AstraZeneca PLC's return on equity of 19.55% beat GSK PLC's return on equity of 23.08%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC83.51% $0.94 $70.9B GSKGSK PLC74.23% $0.99 $41.5B -
What do Analysts Say About AZN or GSK?
AstraZeneca PLC has a consensus price target of $84.18, signalling upside risk potential of 14.46%. On the other hand GSK PLC has an analysts' consensus of $41.54 which suggests that it could grow by 2.58%. Given that AstraZeneca PLC has higher upside potential than GSK PLC, analysts believe AstraZeneca PLC is more attractive than GSK PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 2 0 GSKGSK PLC0 5 1 -
Is AZN or GSK More Risky?
AstraZeneca PLC has a beta of 0.385, which suggesting that the stock is 61.545% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.537, suggesting its less volatile than the S&P 500 by 46.283%.
-
Which is a Better Dividend Stock AZN or GSK?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.11%. GSK PLC offers a yield of 3.95% to investors and pays a quarterly dividend of $0.43 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. GSK PLC pays out 94.91% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or GSK?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than GSK PLC quarterly revenues of $9.5B. AstraZeneca PLC's net income of $2.9B is higher than GSK PLC's net income of $2B. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.54x while GSK PLC's PE ratio is 21.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.18x versus 2.08x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.18x 29.54x $13.6B $2.9B GSKGSK PLC2.08x 21.00x $9.5B $2B
-
Which has Higher Returns AZN or MRNA?
Moderna has a net margin of 21.46% compared to AstraZeneca PLC's net margin of -907.48%. AstraZeneca PLC's return on equity of 19.55% beat Moderna's return on equity of -29.23%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC83.51% $0.94 $70.9B MRNAModerna15.89% -$2.52 $10.1B -
What do Analysts Say About AZN or MRNA?
AstraZeneca PLC has a consensus price target of $84.18, signalling upside risk potential of 14.46%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 83.04%. Given that Moderna has higher upside potential than AstraZeneca PLC, analysts believe Moderna is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 2 0 MRNAModerna4 17 1 -
Is AZN or MRNA More Risky?
AstraZeneca PLC has a beta of 0.385, which suggesting that the stock is 61.545% less volatile than S&P 500. In comparison Moderna has a beta of 1.858, suggesting its more volatile than the S&P 500 by 85.779%.
-
Which is a Better Dividend Stock AZN or MRNA?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.11%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or MRNA?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Moderna quarterly revenues of $107M. AstraZeneca PLC's net income of $2.9B is higher than Moderna's net income of -$971M. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.54x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.18x versus 3.22x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.18x 29.54x $13.6B $2.9B MRNAModerna3.22x -- $107M -$971M
-
Which has Higher Returns AZN or NVAX?
Novavax has a net margin of 21.46% compared to AstraZeneca PLC's net margin of 82.81%. AstraZeneca PLC's return on equity of 19.55% beat Novavax's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC83.51% $0.94 $70.9B NVAXNovavax97.75% $2.93 $94.5M -
What do Analysts Say About AZN or NVAX?
AstraZeneca PLC has a consensus price target of $84.18, signalling upside risk potential of 14.46%. On the other hand Novavax has an analysts' consensus of $14.67 which suggests that it could grow by 108.63%. Given that Novavax has higher upside potential than AstraZeneca PLC, analysts believe Novavax is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC6 2 0 NVAXNovavax3 2 0 -
Is AZN or NVAX More Risky?
AstraZeneca PLC has a beta of 0.385, which suggesting that the stock is 61.545% less volatile than S&P 500. In comparison Novavax has a beta of 2.803, suggesting its more volatile than the S&P 500 by 180.302%.
-
Which is a Better Dividend Stock AZN or NVAX?
AstraZeneca PLC has a quarterly dividend of $1.05 per share corresponding to a yield of 2.11%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 65.8% of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or NVAX?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Novavax quarterly revenues of $626.3M. AstraZeneca PLC's net income of $2.9B is higher than Novavax's net income of $518.6M. Notably, AstraZeneca PLC's price-to-earnings ratio is 29.54x while Novavax's PE ratio is 2.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.18x versus 0.96x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.18x 29.54x $13.6B $2.9B NVAXNovavax0.96x 2.65x $626.3M $518.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Palantir Crash?
AI and data analytics software major Palantir (NASDAQ:PLTR) has been…
Is Target’s Dividend Worth Buying?
Retail giant Target (NYSE:TGT) has been through an extremely volatile…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 41x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
37
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
49
RGC alert for Jun 17
Regencell Bioscience Holdings [RGC] is up 30.47% over the past day.
Buy
75
ARQQ alert for Jun 17
Arqit Quantum [ARQQ] is up 6.36% over the past day.
Buy
59
SYM alert for Jun 17
Symbotic [SYM] is down 3.91% over the past day.
